Syndax Pharmaceuticals (SNDX) Long-Term Investments (2017 - 2025)

Syndax Pharmaceuticals' Long-Term Investments history runs 5 years deep, the most recent figure standing at $20.1 million for Q3 2025.

• On a quarterly basis, Long-Term Investments rose 100.88% year-over-year to $20.1 million in Q3 2025; TTM through Sep 2025 was $20.1 million, a 100.88% increase from a year earlier, with the FY2024 full-year figure at $119.5 million, up 300.68% from the prior year.
• Long-Term Investments retreated to $20.1 million in Q3 2025 per SNDX's latest filing, from $62.6 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $119.5 million in Q4 2024 and bottomed at $5.5 million in Q4 2022.
• The 4-year median for Long-Term Investments is $20.1 million (2025), against an average of $39.9 million.
• Across the five-year window, Long-Term Investments soared 445.42% in 2023 and plunged 36.14% in 2024, its largest moves.
• Year by year, Long-Term Investments stood at $5.5 million in 2022, then surged by 445.42% to $29.8 million in 2023, then jumped by 300.68% to $119.5 million in 2024, then slumped by 83.14% to $20.1 million in 2025.
• Per Business Quant, the three latest SNDX Long-Term Investments figures stand at $20.1 million (Q3 2025), $62.6 million (Q2 2025), and $89.9 million (Q1 2025).